阿奇霉素联合甲强龙治疗支原体肺炎肺实变患儿的随机对照临床试验

doi:10.12092/j.issn.1009-2501.2018.09.014

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (9): 1052-1055.doi: 10.12092/j.issn.1009-2501.2018.09.014

阿奇霉素联合甲强龙治疗支原体肺炎肺实变患儿的随机对照临床试验

张文喜¹，刘东红²，赵蓓¹，赵佳佳¹，蔡俏¹，高未¹，蔡奔奔¹

台州市第一人民医院，¹儿科，²检验科，台州 318020，浙江

收稿日期:2018-05-30 修回日期:2018-07-13 出版日期:2018-09-26 发布日期:2018-09-26
作者简介:张文喜，男，本科，副主任医师，研究方向：儿科呼吸，危重症。 Tel：15105868311 E-mail：mgdawdx@163.com
基金资助:
浙江省医药卫生科技计划项目（2015KYB139）；浙江省台州市科技局课题（15yw05）

A randomized controlled clinical trial of azithromycin combined with methylprednisolone in treating pulmonary consolidation from mycoplasma pneumonia

ZHANG Wenxi¹, LIU Donghong², ZHAO Bei¹, ZHAO Jiajia¹, CAI Qiao¹, GAO Wei¹, CAI Benben¹

¹ Department of Pediatrics,² Department of Clinical Lab, Taizhou First People's Hospital, Taizhou 318020, Zhejiang, China

Received:2018-05-30 Revised:2018-07-13 Online:2018-09-26 Published:2018-09-26

摘要/Abstract

摘要：

目的: 探讨阿奇霉素联合甲强龙治疗支原体肺炎肺实变患儿的临床效果。方法: 82例支原体肺炎肺实变患儿按随机数表法分为对照组和试验组，每组41例。对照组在常规治疗基础上联合阿奇霉素治疗，每次10 mg·kg^-1·d^-1，静脉滴注，qd，持续治疗5 d。试验组在对照组基础上联合甲强龙治疗，每次1 mg/kg，静脉滴注，q12h，持续治疗5 d。比较两组临床疗效、临床症状缓解时间、血清指标和不良反应发生情况。结果: 治疗后，试验组和对照组总有效率分别为90.24%（37/41）和70.73%（29/41），差异有统计学意义（P<0.05）。试验组临床症状缓解时间均少于对照组，差异有统计学意义（P<0.05）。试验组和对照组C反应蛋白（CRP）分别为（14.73±1.84）和（19.64±2.63）mg/L，IL-6分别为（50.49±6.05）和（69.21±7.42）mg/L，血沉（ESR）分别为（27.47±3.30）和（31.11±4.73）mm/h，差异有统计学意义（P<0.05）。两组均有皮疹瘙痒、恶心呕吐发生，试验组和对照组不良反应发生率分别为26.83%（11/41）和12.19%（5/41），差异无统计学意义（P>0.05）。结论: 阿奇霉素联合甲强龙治疗支原体肺炎肺实变患儿的疗效优于阿奇霉素，能够有效缓解临床症状，提高临床效果，且未明显增加药物不良反应发生率。

关键词: 支原体肺炎肺实变, 阿奇霉素, 甲强龙, 随机对照

Abstract:

AIM: To explore the clinical effect of azithromycin combined with methylprednisolone in treating pulmonary consolidation from mycoplasma pneumonia. METHODS: Eighty-two patients with pulmonary consolidation from mycoplasma pneumonia were divided into control group and treatment group according to random number table method. The control group received routine treatment combined with azithromycin of 10 mg·kg^-1·d^-1 (intravenous drip,qd) and for a continuous treatment of 5 days. The treatment group received extra methylprednisolone of 1 mg/kg (intravenous drip,q12h) for a continuous treatment of 5 days on the basis of the control group. The clinical efficacy,clinical symptom relief time, the serum index and the adverse reaction occurred between two groups were compared. RESULTS: After treatment, the total effective rate in the treatment group and the control group was 90.24%(37/41) and 70.73%(29/41), respectively (P<0.05). The clinical symptom relief time in the treatment group was shorter than that of the control group (P<0.05). The C reactive protein (CRP) in the treatment group and the control group was (14.73±1.84) and (19.64±2.63)mg/L, interleukin-6 (IL-6) was (50.49±6.05) and (69.21±7.42) mg/L, erythrocyte sedimentation rate (ESR) was (27.47±3.30) and (31.11±4.73) mm/h,respectively (P<0.05). Both groups had rashes and itching, nausea and vomiting, and the adverse reaction rate in the treatment group and the control group was 26.83% (11/41) and 12.19% (5/41), respectively (P>0.05). CONCLUSION: The combined treatment of azithromycin plus methylprednisolone for pulmonary consolidation from mycoplasma pneumonia is better than azithromycin alone.It can effectively relieve clinical symptoms and improve clinical effect with no significant increase in the incidence of adverse drug reactions.

Key words: pulmonary consolidation from mycoplasma pneumonia, azithromycin, methylprednisolone, randomized controlled

中图分类号:

R563.1

张文喜，刘东红，赵蓓，赵佳佳，蔡俏，高未，蔡奔奔. 阿奇霉素联合甲强龙治疗支原体肺炎肺实变患儿的随机对照临床试验[J]. 中国临床药理学与治疗学, 2018, 23(9): 1052-1055.

ZHANG Wenxi, LIU Donghong, ZHAO Bei, ZHAO Jiajia, CAI Qiao, GAO Wei, CAI Benben. A randomized controlled clinical trial of azithromycin combined with methylprednisolone in treating pulmonary consolidation from mycoplasma pneumonia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1052-1055.

[1]	刘亚东，卢小伟，刘志刚. 促红细胞生成素对急性脊髓损伤患者血清降钙素基因相关肽的影响[J]. 中国临床药理学与治疗学, 2019, 24(8): 933-937.
[2]	刘雅琦，陆梦洁，刘玉秀，陈羽，袁阳丹，周憧憧，刘曼. 倍比分组双盲随机对照试验的盲态分析[J]. 中国临床药理学与治疗学, 2019, 24(10): 1155-1160.
[3]	伍长娟，汤天生. 振源胶囊辅助治疗慢性心力衰竭疗效及安全性的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(3): 299-304.
[4]	李娜，刘桢宇，胡文，陈春林. 氨曲南联用阿奇霉素对产膜铜绿假单胞菌作用的实验研究[J]. 中国临床药理学与治疗学, 2017, 22(12): 1400-1405.
[5]	罗玲玲，滕承志，李晓笑，潘丹峰. 阿奇霉素联合盐酸氨溴索治疗小儿支原体肺炎合并急性支气管炎的临床研究[J]. 中国临床药理学与治疗学, 2017, 22(11): 1278-1282.
[6]	陈嘉仁，崔雨迪，田灏，王昊. 沃替西汀治疗重度抑郁症的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(1): 52-59.
[7]	杭永付，卢国元，沈蕾，高杰，乔青，李明，沙文刚，周玲，丁肖梁，谢诚. 来氟米特治疗IgA肾病安全性和有效性的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(1): 60-67.
[8]	伍艳, 吴翠芳, 汪江林. 利西拉来治疗2型糖尿病的有效性及安全性的Meta分析[J]. 中国临床药理学与治疗学, 2015, 20(2): 167-174.
[9]	樊茂蓉, 王冰, 高金柱, 樊长征, 张琼. 三拗片治疗急性支气管炎(风寒袭肺证)的临床研究[J]. 中国临床药理学与治疗学, 2014, 19(1): 44-47.
[10]	张琼, 苗青, 张燕萍, 樊茂蓉. 参果老年感冒颗粒治疗老年体虚感冒(气虚肺热证)的多中心、随机、双盲、对照试验[J]. 中国临床药理学与治疗学, 2013, 18(9): 1019-1024.
[11]	郑美梅, 王方剑, 岳铁刚, 董丽妍, 段成城. 阿奇霉素对支气管哮喘患者肺功能及血清结缔组织生长因子的影响[J]. 中国临床药理学与治疗学, 2013, 18(2): 194-197.
[12]	钱小英, 吴厉锋, 徐滨. 阿奇霉素对慢性阻塞性肺疾病急性加重患者的免疫调节作用研究[J]. 中国临床药理学与治疗学, 2013, 18(11): 1288-1290.
[13]	王华富, 丁汀, 商振球, 桂志红, 林慧萍, 孙慧伶. 奥曲肽对肝硬化食管胃底静脉曲张破裂出血维持治疗的Meta分析[J]. 中国临床药理学与治疗学, 2012, 17(7): 768-772.
[14]	吴家利, 刘文华, 尹平. 米卡芬净治疗真菌感染的疗效与安全性的Meta分析[J]. 中国临床药理学与治疗学, 2012, 17(1): 64-68.
[15]	高小梅, 王柏松, 宋艳艳, 祁红, 荣征星, 王昊. 针刺治疗偏头痛的系统评价和Meta分析[J]. 中国临床药理学与治疗学, 2011, 16(5): 530-537.

阿奇霉素联合甲强龙治疗支原体肺炎肺实变患儿的随机对照临床试验

A randomized controlled clinical trial of azithromycin combined with methylprednisolone in treating pulmonary consolidation from mycoplasma pneumonia

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价